OTCMKTS:ERGO

Entia Biosciences Stock Forecast, Price & News

$0.04
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.04
Now: $0.04
$0.04
50-Day Range
$0.02
MA: $0.03
$0.04
52-Week Range
$0.01
Now: $0.04
$0.05
VolumeN/A
Average Volume34,223 shs
Market Capitalization$1.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ERGO
CUSIPN/A
Phone971-228-0709
Employees6
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.04 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

No headlines for this company have been tracked by MarketBeat.com

MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1654th out of 2,010 stocks

Medicinals & Botanicals Industry

20th out of 33 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.04
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ERGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ERGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Entia Biosciences (OTCMKTS:ERGO) Frequently Asked Questions

What stocks does MarketBeat like better than Entia Biosciences?

Wall Street analysts have given Entia Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Entia Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Entia Biosciences?

Entia Biosciences saw a increase in short interest in the month of February. As of February 26th, there was short interest totaling 43,200 shares, an increase of 61.2% from the February 11th total of 26,800 shares. Based on an average daily volume of 34,700 shares, the days-to-cover ratio is presently 1.2 days.
View Entia Biosciences' Short Interest
.

How has Entia Biosciences' stock been impacted by Coronavirus?

Entia Biosciences' stock was trading at $0.0065 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ERGO stock has increased by 469.2% and is now trading at $0.0370.
View which stocks have been most impacted by COVID-19
.

Who are Entia Biosciences' key executives?

Entia Biosciences' management team includes the following people:
  • Dr. Marvin S. Hausman, Chairman and Chief Science & Technology Officer (Age 80, Pay $174k)
  • Mr. Timothy A. Timmins, CEO & Pres (Age 64, Pay $141.52k)
  • Mr. Elliot A. L. Shelton, Sec. and Director (Age 71)
  • William Meyer, Head of Production

Who are some of Entia Biosciences' key competitors?

What other stocks do shareholders of Entia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entia Biosciences investors own include Woodward (WWD), Drone Delivery Canada (TAKOF), Centrica (CNA) and Aurora Cannabis (ACB).

What is Entia Biosciences' stock symbol?

Entia Biosciences trades on the OTCMKTS under the ticker symbol "ERGO."

How do I buy shares of Entia Biosciences?

Shares of ERGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entia Biosciences' stock price today?

One share of ERGO stock can currently be purchased for approximately $0.04.

How much money does Entia Biosciences make?

Entia Biosciences has a market capitalization of $1.04 million.

How many employees does Entia Biosciences have?

Entia Biosciences employs 6 workers across the globe.

What is Entia Biosciences' official website?

The official website for Entia Biosciences is www.entiabio.com.

Where are Entia Biosciences' headquarters?

Entia Biosciences is headquartered at 13565 SW TUALATIN-SHERWOOD ROAD. SUITE 800, SHERWOOD OR, 97140.

How can I contact Entia Biosciences?

Entia Biosciences' mailing address is 13565 SW TUALATIN-SHERWOOD ROAD. SUITE 800, SHERWOOD OR, 97140. The biotechnology company can be reached via phone at 971-228-0709.


This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.